Medication info
Januglutide 50 mg (Sitagliptin Hydrochloride Monohydrate)

Januglutide 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tablet
Manufacturer / importer
Sears Pharmaceutical Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202108142 · Approved 2021.12.29 · Insurance code 689001750

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For monotherapy or combination therapy, administer this medicine at a dose of 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Sears Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in controlling blood sugar levels in patients with type 2 diabetes
View approved original text

This medication is an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. For patients who are new to treatment, this medication may be used alone. However, if glycemic control is insufficient with monotherapy, it can be used in combination with metformin. Additionally, when blood sugar levels are not sufficiently controlled by sulfonylurea, metformin, thiazolidinedione, or insulin alone, this medication is added to the regimen. Furthermore, it is used in cases where multiple medications do not adequately control blood sugar levels, assisting in glycemic control across various scenarios.

How to take

Adult dose

For monotherapy or combination therapy, administer this medicine at a dose of 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause serious allergic reactions during use; therefore, if symptoms such as skin rashes or breathing difficulties occur, it should be discontinued immediately and medical advice should be sought. During treatment with this medication, there is a risk of pancreatitis, so if symptoms such as abdominal pain or vomiting occur, medical personnel should be notified immediately. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in those with a severe allergy to this medication or its components. Patients with impaired kidney function need to have their doses adjusted, hence regular kidney function tests are required. Symptoms of hypoglycemia may arise when this medication is used alone or in combination with other diabetes medications, so blood glucose levels should be monitored closely, and if necessary, consult with a physician to adjust the medication dosage. Severe joint pain or skin blistering may occur, and if these symptoms appear, the doctor should be informed immediately, and the medication should be stopped. There may be potential interactions with other medications; therefore, if any medications are currently being taken, it is imperative to inform medical professionals. Pregnant or breastfeeding women are advised not to take this medication, and safety and efficacy have not been established for children and adolescents under 18 years of age. Elderly patients may have reduced kidney function; hence, dose adjustment and kidney function tests are necessary, and in case of overdose, immediate medical treatment is required.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • rhinitis
  • headache
Show 30 more
  • diarrhea
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • arthralgia with severity and disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevation of liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and should be kept at a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.